Labcorp Holdings (FRA:N6B) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:N6B Labcorp Holdings Inc FRA:N6B
78 GF Score
Price €276.00
GF Value €240.24
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Labcorp Holdings Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Labcorp Holdings  (FRA:N6B) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Labcorp Holdings Cyclically Adjusted PS Ratio Related Terms


Labcorp Holdings Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Labcorp Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labcorp Holdings Cyclically Adjusted PS Ratio Chart

Labcorp Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.45 1.76 1.73 1.69 1.56

Labcorp Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.63 1.74 1.53 1.60 1.69

FRA:N6B vs DGX, MTD, ILMN: Cyclically Adjusted PS Ratio Comparison

For the Diagnostics & Research subindustry, Labcorp Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labcorp Holdings Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Labcorp Holdings's Cyclically Adjusted PS Ratio falls into.


FRA:N6B
78GF Score
Labcorp Holdings Inc FRA:N6B
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labcorp Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Labcorp Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Labcorp Holdings's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=39.134/333.9520*333.9520
=39.134

Current CPI (Jun. 2026) = 333.9520.

Labcorp Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 20.626 241.428 28.531
201612 21.427 241.432 29.638
201703 21.713 243.801 29.742
201706 22.154 244.955 30.203
201709 21.538 246.819 29.141
201712 22.479 246.524 30.451
201803 22.414 249.554 29.994
201806 23.357 251.989 30.954
201809 23.702 252.439 31.355
201812 24.139 251.233 32.087
201903 24.706 254.202 32.457
201906 25.958 256.143 33.843
201909 26.795 256.759 34.851
201912 27.220 256.974 35.374
202003 26.370 258.115 34.118
202006 25.735 257.797 33.337
202009 34.000 260.280 43.624
202012 38.311 260.474 49.118
202103 35.076 264.877 44.223
202106 32.467 271.696 39.906
202109 35.492 274.310 43.209
202112 36.888 278.802 44.185
202203 36.980 287.504 42.954
202206 29.588 296.311 33.347
202209 31.379 296.808 35.306
202212 40.497 296.797 45.567
202303 31.812 301.836 35.197
202306 31.319 305.109 34.280
202309 32.297 307.789 35.042
202312 33.230 306.746 36.177
202403 34.555 312.332 36.947
202406 35.489 314.175 37.723
202409 35.398 315.301 37.492
202412 37.069 315.605 39.224
202503 37.703 319.799 39.372
202506 37.092 322.561 38.402
202509 36.431 324.800 37.458
202512 36.306 324.054 37.415
202603 36.475 330.213 36.888
202606 39.134 333.952 39.134

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Labcorp Holdings (FRA:N6B) Overvalued in 2026?

Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued. The current stock price of €276.00 is trading 14.9% above its estimated GF Value™ of €240.24. GuruFocus considers Labcorp Holdings to be Modestly Overvalued.

Key valuation signals for FRA:N6B:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €240.24 vs. price of €276.00 (14.9% above fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the FRA:N6B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Labcorp Holdings Business Description

Other Exchanges LH:USA0JSY:UKN6B:Germany
Address 358 South Main Street, Burlington, NC, USA, 27215
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
78GF Score

Get the complete analysis for FRA:N6B

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€276.00
Price
€240.24
GF Value